Redefining Cancer Care: Highlights from ESMO 2025

October 23, 2025

Cancer remains one of the greatest healthcare challenges of our lifetime – with approximately 20 million people around the world receiving a new cancer diagnosis each year¹. As such, Oncology is a core therapeutic area for Pfizer, and we are dedicated to redefining the standard of care in cancer through continued research and scientific innovation. Our team is rapidly advancing new potential treatments across multiple disease areas, driven by the goal of reshaping outcomes for people living with cancer.

At the recent 2025 European Society for Medical Oncology (ESMO) Congress, Pfizer shared new data from our industry-leading portfolio and extensive pipeline. We presented findings from more than 45 research abstracts throughout the five-day event in Berlin, sharing insights with clinicians in attendance that could ultimately inform their clinical practice (pending clinical trial success and approval).

“The findings presented at ESMO 2025 illustrate continued momentum across Pfizer’s Oncology organization. Our progress – including meaningful survival benefits across multiple cancer types – reinforces our commitment to driving the next generation of breakthroughs that have the potential to transform care for people living with cancer.”

– Dr. Jeff Legos, Chief Oncology Officer

Key Highlights from Pfizer’s ESMO 2025 Presentations

PADCEV: Unprecedented survival data in muscle-invasive bladder cancer

Phase 3 trial results show the potential of PADCEV™, in combination with KEYTRUDA™, to redefine the standard of care for certain patients with bladder cancer.

XTANDI: Unprecedented survival data in advanced prostate cancer

Phase 3 trial results demonstrate the profound impact of XTANDI®, in combination with hormone therapy, on clinical outcomes for men with certain types of advanced prostate cancer.

BRAFTOVI: Sustained long-term survival data in advanced lung cancer

Updated Phase 2 trial results evaluating BRAFTOVI® + MEKTOVI® set a new benchmark for patients who have advanced lung cancer with a specific mutation.

These results highlight the next wave of potential breakthroughs in cancer and underscore the depth and breadth of Pfizer’s Oncology research – which is driving our pursuit of innovative medicines that bring new hope to people living with cancer worldwide.

¹World. Global Cancer Observatory. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf

Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC's website.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.